PLoS ONE · 2018 · 88 citations · 44 references
MedicineCardiologyGeriatric MedicineDementiaGeriatric PharmacotherapyGeriatricsDementia EpidemiologyDementia PreventionDementia Risk FactorsHypertension ManagementMedication UsePharmacoepidemiologyAlzheimer Disease DementiaAlzheimer Disease EpidemiologyAlzheimer's Disease PreventionAngiotensin Ii Receptor BlockersAntihypertensive Medication ClassesMatched Cohort DesignPharmacy Claims Analysis
BACKGROUND: Antihypertensive treatments have been shown to reduce the risk of Alzheimer's disease (AD). The renin-angiotensin system (RAS) has been implicated in AD, and thus RAS-acting AHTs (angiotensin converting enzyme inhibitors (ACEIs), and angiotensin-II receptor blockers (ARBs)) may offer differential and additional protective benefits against AD compared with other AHTs, in addition to hypertension management. METHODS: In a retrospective cohort design, we examined the medical and pharmacy claims of a 20% sample of Medicare beneficiaries from 2007 to 2013, and compared rates of AD diagnosis for 1,343,334 users of six different AHT drug treatments, 65 years of age or older (4,215,338 person-years). We compared AD risk between RAS and non-RAS AHT drug users, and between ACEI users and ARB users, by sex and race/ethnicity. Models adjusted for age, socioeconomic status, underlying health, and comorbidities. FINDINGS: RAS-acting AHTs were slightly more protective against onset of AD than non-RAS-acting AHTs for males, (male OR = 0.931 (CI: 0.895-0.969)), but not so for females (female OR = 0.985 (CI: 0.963-1.007)). Relative to other AHTs, ARBs were superior to ACEIs for both men (male ARB OR = 0.834 (CI: 0.788-0.884); male ACEI OR = 0.978 (CI: 0.939-1.019)) and women (female ARB OR = 0.941 (CI: 0.913-0.969); female ACEI OR = 1.022 (CI: 0.997-1.048)), but only in white men and white and black women. No association was shown for Hispanic men and women. CONCLUSION: Hypertension management treatments that include RAS-acting ARBs may, in addition to lowering blood pressure, reduce AD risk, particularly for white and black women and white men. Additional studies and clinical trials that include men and women from different racial and ethnic groups are needed to confirm these findings. Understanding the potentially beneficial effects of certain RAS-acting AHTs in high-risk populations is of great importance.
44
Heart disease and stroke statistics--2015 update: a report from the American Heart Association.
Dariush Mozaffarian, Emelia J. Benjamin, Alan S. Go et al. · PubMed · 2015 · 8.3K citations
Heart Disease and Stroke Statistics—2014 Update
Alan S. Go, Dariush Mozaffarian, Véronique L. Roger et al. · Circulation · 2013 · 5.2K citations · Full text
2018 Alzheimer's disease facts and figures
Alzheimer s & Dementia · 2018 · 1.9K citations
2017 Alzheimer's disease facts and figures
Alzheimer s & Dementia · 2017 · 1.3K citations